RxDoctor Payments Data

Lovedhi Aggarwal, MD

Geriatric Medicine · East Setauket, NYNPI 1760668933

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.1% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 34.8% of the total.

$1,840in general payments, 2019–2025

Across 28 payments — averaging $65.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$640
  • Esperion Therapeutics, Inc.$350
  • Gilead$263
  • Lilly USA, LLC$234
  • Johnson & Johnson$124
  • Intuity Medical Inc$124
  • plus $105 from 3 others

What the payments were for

  • Speaking & faculty fees$603%
  • Food & beverage$1,76896%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,840 in reported general payments places this provider in the 85th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$71,319
Medicare patients
160
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$30,281
TrulicityDulaglutide14$20,611
XareltoRivaroxaban16$20,441
MounjaroTirzepatide16$19,885
JardianceEmpagliflozin13$14,251
Famotidine35$4,755
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,013
Atorvastatin Calcium193$1,738
Gabapentin81$1,628
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$1,548
Levothyroxine Sodium87$1,286
Rosuvastatin Calcium83$1,278
Montelukast Sodium68$1,236
Albuterol Sulfate HfaAlbuterol Sulfate47$1,139
GenerlacLactulose25$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$234$40,49630 claims
Johnson & JohnsonXarelto$124$20,44116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →